COMPLETED

Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost

Talk to us

Conditions

Normal Tension Glaucoma

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

A randomized, multicenter, investigator-masked prospective study of NTG patients currently on latanoprost 0.005% monotherapy, to study the effect of IOP change with the introduction of netarsudil 0.02% vs brimonidine 0.1%. Subjects will be assessed at a screening visit, and 1 follow-up visit. Clinical evaluations will include visual acuity and IOP .

Official Title

Effect of the Addition of Netarsudil 0.02% vs. Brimonidine 0.1% in Normal Tension Glaucoma Patients Currently on Latanoprost 0.005%

Quick Facts

Study Start:2024-06-13
Study Completion:2025-09-22
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT06449352

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients 18 years and older
  2. * Diagnosed with normal tension glaucoma based on the following:
  3. * IOP ≤ 21mmHg
  4. * Optic nerve rim thinning and/or retinal nerve fiber layer (RNFL) loss consistent with glaucoma
  5. * Normal visual field OR visual field loss consistent with optic nerve or RNFL defects within the last year
  6. * Open angles assessed by gonioscopy
  7. * Have been on latanoprost monotherapy for at least 6 weeks
  1. * Patients with angle closure glaucoma or secondary forms of glaucoma due to neovascularization of the angle, uveitic glaucoma, congenital glaucoma, or glaucoma due to congenital anomalies.
  2. * Other forms of secondary glaucoma.
  3. * Patients with abnormal anterior segment examination other than cataract will be excluded from the study.
  4. * Patients who have had incisional surgery for glaucoma (eg: MIGs).
  5. * Patients with refractory CME or CME persisting 3 months or more.
  6. * Children, cognitive impaired and critically ill subjects will not be enrolled.
  7. * Central Corneal Thickness (CCT) ≤ 500.
  8. * Prior allergy to brimonidine or netarsudil, and known to have previously failed either brimonidine or netarsudil.
  9. * Ocular surgery (e.g., cataract, laser, refractive) during the study or 1 year prior to entering the study.

Contacts and Locations

Principal Investigator

Zarmeena Vendal, MD
PRINCIPAL_INVESTIGATOR
Westlake Eye Specialists

Study Locations (Sites)

Westlake Eye Specialists - Austin Office
Austin, Texas, 78746
United States
Westlake Eye Specialists - Killeen Office
Killeen, Texas, 76549
United States
Westlake Eye Specialists - Kyle Office
Kyle, Texas, 78640
United States
Westlake Eye Specialists - New Braunfels Office
New Braunfels, Texas, 78130
United States

Collaborators and Investigators

Sponsor: Westlake Eye Specialists

  • Zarmeena Vendal, MD, PRINCIPAL_INVESTIGATOR, Westlake Eye Specialists

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-06-13
Study Completion Date2025-09-22

Study Record Updates

Study Start Date2024-06-13
Study Completion Date2025-09-22

Terms related to this study

Additional Relevant MeSH Terms

  • Normal Tension Glaucoma